Hydroxychloroquine Therapy in Sarcoidosis-Associated Uveitis.

Hydroxychloroquine sarcoidosis uveitis

Journal

Ocular immunology and inflammation
ISSN: 1744-5078
Titre abrégé: Ocul Immunol Inflamm
Pays: England
ID NLM: 9312169

Informations de publication

Date de publication:
07 Feb 2023
Historique:
entrez: 7 2 2023
pubmed: 8 2 2023
medline: 8 2 2023
Statut: aheadofprint

Résumé

To assess the efficacy and tolerance of hydroxychloroquine in sarcoidosis-associated uveitis. Retrospective study on all patients with sarcoidosis-associated uveitis who were treated with hydroxychloroquine between 2003 and 2019 in a French university hospital. Twenty-seven patients with sarcoidosis-associated uveitis received hydroxychloroquine. The mean duration of treatment was 20.0 ± 10.9 months. At the end of the follow-up, hydroxychloroquine success was achieved in 15 (55.6%) patients. Four of them were also on oral corticosteroids, with a prednisone dose ≤5 mg/day. Under treatment, the median prednisone dose decreased from 20.0 (interquartile range (IQR), 7-25) to 5.0 (IQR, 3-6.5) mg/day ( Hydroxychloroquine appears as an interesting option in sarcoidosis-associated uveitis.

Sections du résumé

BACKGROUND/PURPOSE UNASSIGNED
To assess the efficacy and tolerance of hydroxychloroquine in sarcoidosis-associated uveitis.
METHODS UNASSIGNED
Retrospective study on all patients with sarcoidosis-associated uveitis who were treated with hydroxychloroquine between 2003 and 2019 in a French university hospital.
RESULTS UNASSIGNED
Twenty-seven patients with sarcoidosis-associated uveitis received hydroxychloroquine. The mean duration of treatment was 20.0 ± 10.9 months. At the end of the follow-up, hydroxychloroquine success was achieved in 15 (55.6%) patients. Four of them were also on oral corticosteroids, with a prednisone dose ≤5 mg/day. Under treatment, the median prednisone dose decreased from 20.0 (interquartile range (IQR), 7-25) to 5.0 (IQR, 3-6.5) mg/day (
CONCLUSION UNASSIGNED
Hydroxychloroquine appears as an interesting option in sarcoidosis-associated uveitis.

Identifiants

pubmed: 36749910
doi: 10.1080/09273948.2023.2165952
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-7

Auteurs

Arthur Bert (A)

Department of Internal Medicine, University Hospital Lyon Croix-Rousse, Claude Bernard University - Lyon 1, Lyon, France.

Thomas El Jammal (T)

Department of Internal Medicine, University Hospital Lyon Croix-Rousse, Claude Bernard University - Lyon 1, Lyon, France.

Laurent Kodjikian (L)

Department of Ophthalmology, University Hospital Lyon Croix-Rousse, University Claude Bernard University - Lyon 1, Lyon, France.

Mathieu Gerfaud-Valentin (M)

Department of Internal Medicine, University Hospital Lyon Croix-Rousse, Claude Bernard University - Lyon 1, Lyon, France.

Yvan Jamilloux (Y)

Department of Internal Medicine, University Hospital Lyon Croix-Rousse, Claude Bernard University - Lyon 1, Lyon, France.

Pascal Seve (P)

Department of Internal Medicine, University Hospital Lyon Croix-Rousse, Claude Bernard University - Lyon 1, Lyon, France.
Research on Healthcare Performance (RESHAPE), INSERM U1290, Université Claude Bernard Lyon 1, Lyon, France.

Classifications MeSH